Diaceutics PLC Director/PDMR/PCA Shareholding & TR1
April 02 2024 - 2:00AM
RNS Regulatory News
RNS Number : 8170I
Diaceutics PLC
02 April 2024
Director / PDMR /
PCA Shareholding & TR-1 Notification
Belfast and London, 2 April 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions
provider to the pharma and biotech industry, announces that on 28
March 2024, Peter Keeling, co-founder and Executive Director of
Diaceutics, and Delia Keeling (Peter Keeling's spouse and a PCA),
cumulatively sold 1,500,000 ordinary shares of £0.002 each in the
Company ("Ordinary Shares") at a price of 102 pence per
Ordinary Share. As a result of the sale, Peter and Delia
Keeling's combined shareholding in Diaceutics is 15,752,049
Ordinary Shares representing approximately 18.60% of the Company's
issued share capital.
This announcement contains inside
information for the purposes of Article 7 of Regulation (EU)
596/2014 as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in
accordance with the Company's obligations under Article 17 of MAR.
The person responsible for making this announcement on behalf of
the Company is Nick Roberts, Chief Financial Officer.
Enquiries:
Diaceutics PLC
|
|
Ryan Keeling, Chief Executive Officer
Nick Roberts, Chief Financial
Officer
|
Tel: +44 (0)28 9040 6500
investorrelations@diaceutics.com
|
|
|
Stifel Nicolaus Europe Limited (Nomad &
Broker)
|
Tel: +44 (0)20 7710
7600
|
Ben Maddison
|
|
Nick Harland
|
|
Kate Hanshaw
|
|
|
|
Alma Strategic Communications
|
Tel: +44(0)20 3405
0205
|
Caroline Forde, Kinvara Verdon, Kieran Breheny
|
diaceutics@almastrategic.com
|
|
|
About Diaceutics
At Diaceutics we believe that every
patient should get the opportunity to receive the right test and
the right therapy to positively impact their disease
outcome.
We provide the world's leading
pharma and biotech companies with an end-to-end commercialisation
solution for precision medicines through data analytics, scientific
and advisory services enabled by our platform DXRX - The
Diagnostics Network ®.
Notification of a Transaction pursuant to Article 19(1) of
Regulation (EU) No. 596/2014
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
a.
|
Name
|
Peter Keeling
|
2
|
Reason for notification
|
|
a.
|
Position/Status
|
Executive Director
|
b.
|
Initial notification/
Amendment
|
Initial
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a.
|
Name
|
Diaceutics PLC
|
b.
|
LEI
|
213800VEWQBB39ZB8J81
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a.
|
Description of the financial
instrument, type of instrument
Identification Code
|
Ordinary shares of
£0.002 each
ISIN: GB00BJQTGV64
|
b.
|
Nature of the transaction
|
Sale
|
c.
|
Price(s) and volume(s)
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
£1.02
|
750,000
|
|
|
d.
|
Date of the transaction
|
28 March 2024
|
e.
|
Place of the transaction
|
AIM Market of the London Stock
Exchange
|
Notification of a Transaction pursuant to Article 19(1) of
Regulation (EU) No. 596/2014
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
a.
|
Name
|
Delia Keeling
|
2
|
Reason for notification
|
|
a.
|
Position/Status
|
PCA
|
b.
|
Initial notification/
Amendment
|
Initial
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a.
|
Name
|
Diaceutics PLC
|
b.
|
LEI
|
213800VEWQBB39ZB8J81
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a.
|
Description of the financial
instrument, type of instrument
Identification Code
|
Ordinary shares of
£0.002 each
ISIN: GB00BJQTGV64
|
b.
|
Nature of the transaction
|
Sale
|
c.
|
Price(s) and volume(s)
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
£1.02
|
750,000
|
|
|
d.
|
Date of the transaction
|
28 March 2024
|
e.
|
Place of the transaction
|
AIM Market of the London Stock
Exchange
|
TR-1:
Standard form for notification of major
holdings
NOTIFICATION OF MAJOR HOLDINGS
|
1a.
Identity of the issuer or the underlying issuer of existing shares
to which voting rights are attached ii:
|
Diaceutics PLC ORD GBP0.002
|
1b.
Please indicate if the issuer is a non-UK
issuer (please mark with an
"X" if appropriate)
|
Non-UK issuer
|
|
2.
Reason for the notification (please
mark the appropriate box or boxes with an "X")
|
An acquisition or disposal of voting
rights
|
X
|
An acquisition or disposal of
financial instruments
|
|
An event changing the breakdown of
voting rights
|
|
Other (please specify)
iii:
|
|
3.
Details of person subject to the notification
obligation iv
|
Name
|
Peter & Delia Keeling
|
City and country of registered office
(if applicable)
|
NA
|
4.
Full name of shareholder(s) (if
different from 3.) v
|
Name
|
|
City and country of registered office
(if applicable)
|
|
5.
Date on which the threshold was crossed or reached
vi:
|
28 March, 2024
|
6.
Date on which issuer
notified:
|
28 March, 2024
|
7.
Total positions of person(s) subject to the notification
obligation
|
|
% of
voting rights attached to shares (total of 8. A)
|
% of
voting rights through financial instruments
(total of 8.B 1 + 8.B 2)
|
Total of
both in % (8.A + 8.B)
|
Total number of voting rights held in
issuer (8.A + 8.B) vii
|
Resulting situation on the date on
which threshold was crossed or reached
|
18.60%
|
|
18.60%
|
|
Position of previous notification (if
applicable)
|
20.37%
|
|
20.37%
|
|
|
|
|
|
|
|
|
8.
Notified details of the resulting situation on the date on which
the threshold was crossed or reached
viii
|
A:
Voting rights attached to shares
|
Class/type of
shares
ISIN code (if possible)
|
Number of voting rights ix
|
% of
voting rights
|
Direct
(DTR5.1)
|
Indirect
(DTR5.2.1)
|
Direct
(DTR5.1)
|
Indirect
(DTR5.2.1)
|
GB00BJQTGV64
|
|
15,752,049
|
|
18.60%
|
|
|
|
|
|
|
|
|
|
|
SUBTOTAL 8. A
|
15,752,049
|
|
|
B 1:
Financial Instruments according to DTR5.3.1R (1)
(a)
|
Type
of financial instrument
|
Expiration
date x
|
Exercise/
Conversion Period xi
|
Number of voting rights that may be acquired if the instrument
is
exercised/converted.
|
% of
voting rights
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUBTOTAL 8. B 1
|
|
|
|
B 2:
Financial Instruments with similar economic effect according to
DTR5.3.1R (1) (b)
|
Type
of financial instrument
|
Expiration
date x
|
Exercise/
Conversion Period xi
|
Physical or cash
Settlement xii
|
Number of voting rights
|
% of
voting rights
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUBTOTAL 8.B.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9.
Information in relation to the person subject to the notification
obligation (please mark the
applicable box with an "X")
|
Person subject to the notification
obligation is not controlled by any natural person or legal entity
and does not control any other undertaking(s) holding directly or
indirectly an interest in the (underlying) issuer
xiii
|
|
Full chain of
controlled undertakings through which the voting rights and/or
the
financial instruments are effectively held starting with the
ultimate controlling natural person or legal entity (please add additional rows as necessary)
xiv
|
|
Name
xv
|
% of voting rights if it
equals or is higher than the notifiable threshold
|
% of voting rights through
financial instruments if it equals or is higher than the notifiable
threshold
|
Total of both if it equals or
is higher than the notifiable threshold
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.
In case of proxy voting, please identify:
|
Name of the proxy holder
|
|
The number and % of voting rights
held
|
|
The date until which the voting
rights will be held
|
|
|
11.
Additional information xvi
|
|
|
|
|
|
|
Place of completion
|
AIM Stock Exchange,
London
|
Date of completion
|
28, March 2024
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHUWVWRSOUOUAR
Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2024 to Jun 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Jun 2023 to Jun 2024